These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 30085126)

  • 21. Functional selectivity and classical concepts of quantitative pharmacology.
    Urban JD; Clarke WP; von Zastrow M; Nichols DE; Kobilka B; Weinstein H; Javitch JA; Roth BL; Christopoulos A; Sexton PM; Miller KJ; Spedding M; Mailman RB
    J Pharmacol Exp Ther; 2007 Jan; 320(1):1-13. PubMed ID: 16803859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Systematic Review of Inverse Agonism at Adrenoceptor Subtypes.
    Michel MC; Michel-Reher MB; Hein P
    Cells; 2020 Aug; 9(9):. PubMed ID: 32825009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inverse agonism: more than reverting constitutively active receptor signaling.
    Dupré DJ; Rola-Pleszczynski M; Stanková J
    Biochem Cell Biol; 2004 Dec; 82(6):676-80. PubMed ID: 15674435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inverse, protean, and ligand-selective agonism: matters of receptor conformation.
    Kenakin T
    FASEB J; 2001 Mar; 15(3):598-611. PubMed ID: 11259378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery.
    Sengmany K; Singh J; Stewart GD; Conn PJ; Christopoulos A; Gregory KJ
    Neuropharmacology; 2017 Mar; 115():60-72. PubMed ID: 27392634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy as a vector: the relative prevalence and paucity of inverse agonism.
    Kenakin T
    Mol Pharmacol; 2004 Jan; 65(1):2-11. PubMed ID: 14722230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional selectivity and biased receptor signaling.
    Kenakin T
    J Pharmacol Exp Ther; 2011 Feb; 336(2):296-302. PubMed ID: 21030484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of cannabinoid CB
    Salort G; Álvaro-Bartolomé M; García-Sevilla JA
    Psychopharmacology (Berl); 2017 Mar; 234(6):925-941. PubMed ID: 28127623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. When simple agonism is not enough: emerging modalities of GPCR ligands.
    Smith NJ; Bennett KA; Milligan G
    Mol Cell Endocrinol; 2011 Jan; 331(2):241-7. PubMed ID: 20654693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modeling and simulation of inverse agonism dynamics.
    Bridge LJ
    Methods Enzymol; 2010; 485():559-82. PubMed ID: 21050936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antipsychotic drug action: antagonism, inverse agonism or partial agonism.
    Strange PG
    Trends Pharmacol Sci; 2008 Jun; 29(6):314-21. PubMed ID: 18471899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ligand bias and inverse agonism on 5-HT
    Muneta-Arrate I; Miranda-Azpiazu P; Horrillo I; Diez-Alarcia R; Meana JJ
    Br J Pharmacol; 2024 Apr; ():. PubMed ID: 38644550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Constitutive coupling of a chimeric dopamine D2/alpha 1B receptor to the phospholipase C pathway: inverse agonism to silent antagonism by neuroleptic drugs.
    Wurch T; Boutet-Robinet EA; Palmier C; Colpaert FC; Pauwels PJ
    J Pharmacol Exp Ther; 2003 Jan; 304(1):380-90. PubMed ID: 12490615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural requirements for inverse agonism and neutral antagonism of indole-, benzimidazole-, and thienopyrrole-derived histamine H4 receptor ligands.
    Schneider EH; Strasser A; Thurmond RL; Seifert R
    J Pharmacol Exp Ther; 2010 Aug; 334(2):513-21. PubMed ID: 20484153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The nature of efficacy at G protein-coupled receptors.
    Zhao P; Furness SGB
    Biochem Pharmacol; 2019 Dec; 170():113647. PubMed ID: 31585071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current topics in angiotensin II type 1 receptor research: Focus on inverse agonism, receptor dimerization and biased agonism.
    Takezako T; Unal H; Karnik SS; Node K
    Pharmacol Res; 2017 Sep; 123():40-50. PubMed ID: 28648738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physiological relevance of constitutive activity of 5-HT2A and 5-HT2C receptors.
    Berg KA; Harvey JA; Spampinato U; Clarke WP
    Trends Pharmacol Sci; 2005 Dec; 26(12):625-30. PubMed ID: 16269190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Some implications of receptor theory for in vivo assessment of agonists, antagonists and inverse agonists.
    Negus SS
    Biochem Pharmacol; 2006 Jun; 71(12):1663-70. PubMed ID: 16460689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of new drugs that act through membrane receptors and involve an action of inverse agonism.
    Rodríguez-Puertas R; Barreda-Gómez G
    Recent Pat CNS Drug Discov; 2006 Jun; 1(2):207-17. PubMed ID: 18221203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery.
    Bond RA; Ijzerman AP
    Trends Pharmacol Sci; 2006 Feb; 27(2):92-6. PubMed ID: 16406086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.